Taysha Gene Therapies, Inc. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| Manning Paul B | — | Gift | 80,000 | — | — | 3,195,205 | Dec 31, 2020 |
| Manning Paul B | — | C | 2,008,158 | — | — | 2,008,158 | Sep 28, 2020 |
| Nagendran Sukumar | — | C | 19,226 | — | — | 19,226 | Sep 28, 2020 |
| Nolan Sean P. | — | C | 1,089,500 | — | — | 1,089,500 | Sep 28, 2020 |
| PRASAD SUYASH | CMO and Head of R&D | C | 3,844 | — | — | 672,589 | Sep 28, 2020 |
| Alam Kamran | Chief Financial Officer | Award / Grant | 331,121 | — | — | 331,121 | Sep 23, 2020 |
| PRASAD SUYASH | CMO and Head of R&D | Award / Grant | 668,745 | — | — | 668,745 | Sep 23, 2020 |